Anne Myhr

Dr. Anne Myhr


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2021 in Transgenic Research
Verified
Journal Article
Open access
PDF file
AOArinze Stanley Okoli
Arinze Stanley Okoli
TBTorill Blix
Torill Blix
AMAnne Myhr
Anne Myhr
WXWenteng Xu
Wenteng Xu
XXXiaodong Xu
Xiaodong Xu
Aquaculture is becoming the primary source of seafood for human diets, and farmed fish aquaculture is one of its fastest growing sectors. The industry currently faces several challenges including infectious and parasitic diseases, reduced viability, fertility reduction, slow growth, escapee fish and environmental pollution. The commercialization of the growth-enhanced AquAdvantage salmon and the CRISPR/Cas9-developed tilapia (Oreochromis niloticus) proffers genetic engineering and genome editing tools, e.g. CRISPR/Cas, as potential solutions to these challenges. Future traits being developed in different fish species include disease resistance, sterility, and enhanced growth. Despite these notable advances, off-target effect and non-clarification of trait-related genes among other technical challenges hinder full realization of CRISPR/Cas potentials in fish breeding. In addition, current regulatory and risk assessment frameworks are not fit-for purpose regarding the challenges of CRISPR/Cas notwithstanding that public and regulatory acceptance are key to commercialization of products of the new technology. In this study, we discuss how CRISPR/Cas can be used to overcome some of these limitations focusing on diseases and environmental release in farmed fish aquaculture. We further present technical limitations, regulatory and risk assessment challenges of the use of CRISPR/Cas, and proffer research strategies that will provide much-needed data for regulatory decisions, risk assessments, increased public awareness and sustainable applications of CRISPR/Cas in fish aquaculture with emphasis on Atlantic salmon (Salmo salar) breeding.

19 February 2014 in Veterinary Research
Verified
Journal Article
Open access
PDF file
LHLinn B Hølvold
Linn B Hølvold
AMAnne Myhr
Anne Myhr
Roy Ambli DalmoRoy Ambli Dalmo
Roy Ambli Dalmo
DNA vaccinations against fish viral diseases as IHNV at commercial level in Canada against VHSV at experimental level are both success stories. DNA vaccination strategies against many other viral diseases have, however, not yet yielded sufficient results in terms of protection. There is an obvious need to combat many other viral diseases within aquaculture where inactivated vaccines fail. There are many explanations to why DNA vaccine strategies against other viral diseases fail to induce protective immune responses in fish. These obstacles include: 1) too low immunogenicity of the transgene, 2) too low expression of the transgene that is supposed to induce protection, 3) suboptimal immune responses, and 4) too high degradation rate of the delivered plasmid DNA. There are also uncertainties with regard distribution and degradation of DNA vaccines that may have implications for safety and regulatory requirements that need to be clarified. By combining plasmid DNA with different kind of adjuvants one can increase the immunogenicity of the transgene antigen – and perhaps increase the vaccine efficacy. By using molecular adjuvants with or without in combination with targeting assemblies one may expect different responses compared with naked DNA. This includes targeting of DNA vaccines to antigen presenting cells as a central factor in improving their potencies and efficacies by means of encapsulating the DNA vaccine in certain carriers systems that may increase transgene and MHC expression. This review will focus on DNA vaccine delivery, by the use of biodegradable PLGA particles as vehicles for plasmid DNA mainly in fish.

21 December 2018 in Frontiers in Plant Science
Verified
Journal Article
Open access
Sarah Agapito-TenfenSarah Agapito-Tenfen
Sarah Agapito-Tenfen
AOArinze Stanley Okoli
Arinze Stanley Okoli
MBMichael J. Bernstein
Michael J. Bernstein
OWOdd-Gunnar Wikmark
Odd-Gunnar Wikmark
AMAnne Myhr
Anne Myhr
New and emerging gene-editing techniques make it possible to target specific genes in species with greater speed and specificity than previously possible. Of major relevance for plant breeding, regulators and scientists are discussing how to regulate products developed using these gene-editing techniques. Such discussions include whether to adopt or adapt the current framework for GMO risk governance in evaluating the impacts of gene-edited plants, and derived products, on the environment, human and animal health and society. Product classification or definition is one of several aspects of the current framework being criticized. Further, knowledge gaps related to risk assessments of gene-edited organisms-for example of target and off-target effects of intervention in plant genomes-are also of concern. Resolving these and related aspects of the current framework will involve addressing many subjective, value-laden positions, for example how to specify protection goals through ecosystem service approaches. A process informed by responsible research and innovation practices, involving a broader community of people, organizations, experts, and interest groups, could help scientists, regulators, and other stakeholders address these complex, value-laden concerns related to gene-editing of plants with and for society.

26 May 2021 in Reviews in Aquaculture
Verified
Journal Article
Open access
PDF file
TBTorill Bakkelund Blix
Torill Bakkelund Blix
Roy Ambli DalmoRoy Ambli Dalmo
Roy Ambli Dalmo
AWAnna Wargelius
Anna Wargelius
AMAnne Myhr
Anne Myhr
Novel genome editing techniques allow for efficient and targeted improvement of aquaculture stock and might be a solution to solve challenges related to disease and environmental impacts. This review has retrieved the latest research on genome editing on aquacultured finfish species, exploring the technological progress and the scope. Genome editing has most often been used on Nile tilapia (Oreochromis niloticus Linnaeus), followed by Atlantic salmon (Salmo salar Linnaeus). More than half of the studies have focused on developing solutions for aquaculture challenges, while the rest can be characterized as basic research on fish genetics/physiology or technology development. Main traits researched are reproduction and development, growth, pigmentation, disease resistance, use of trans‐GFP and study of the omega‐3 metabolism, respectively. There is a certain correlation between the species identified and their commercial relevance, indicating the relevance of most studies for present challenges of aquaculture. Reviewing geographical origin of the research, China has been in the forefront (29 publications), followed by the United States (9) and Norway (7). The research seems not to be dependent on regulative conditions in the respective countries, but merely on the purpose and objectives for the use of genome editing technologies. Some technical barriers identified in the studies are presented together with solutions to overcome these‐off‐target effects, ancestral genome duplication and mosaicism in F0. One of the objectives for use is the contribution to a more sustainable aquaculture, where the most prominent issues are solutions that contribute to minimizing impact on biodiversity.

12 June 2010 in Journal of Agricultural and Environmental Ethics
Verified
Journal Article
Closed access
PDF file
Ingrid OlesenIngrid Olesen
Ingrid Olesen
AMAnne Myhr
Anne Myhr
GRG. Kristin Rosendal
G. Kristin Rosendal

Verified
Journal Article
Open access
AMAnne Myhr
Anne Myhr
DNA vaccines have great potential as preventive or therapeutic vaccines against viral, bacterial, or parasitic diseases as well as cancer, and may also be used as gene therapy products. Although many human and veterinary DNA vaccines have been investigated in laboratory trials, only four of these have been approved for commercial use. In this paper an overview of the regulatory requirements for the development of DNA vaccines is given. The regulatory process in EU and USA is described. A discussion concerning the relevance of national regulations on gene technology is included. In addition the main safety concerns associated with DNA vaccines, relating to unwanted side effects in the vaccinated mammal or fish, are presented. Finally, the need for greater openness regarding the assessment information is discussed.